Eli Lilly and Co (LLY)
760.14
-11.41
(-1.48%)
USD |
NYSE |
May 10, 16:00
760.06
-0.08
(-0.01%)
After-Hours: 19:34
Eli Lilly Enterprise Value: 757.00B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 757.00B |
| May 08, 2024 | 760.27B |
| May 07, 2024 | 762.91B |
| May 06, 2024 | 752.37B |
| May 03, 2024 | 722.23B |
| May 02, 2024 | 742.13B |
| May 01, 2024 | 761.94B |
| April 30, 2024 | 766.07B |
| April 29, 2024 | 724.35B |
| April 26, 2024 | 720.84B |
| April 25, 2024 | 712.63B |
| April 24, 2024 | 719.60B |
| April 23, 2024 | 732.42B |
| April 22, 2024 | 718.77B |
| April 19, 2024 | 714.00B |
| April 18, 2024 | 732.66B |
| April 17, 2024 | 737.24B |
| April 16, 2024 | 733.41B |
| April 15, 2024 | 737.24B |
| April 12, 2024 | 738.07B |
| April 11, 2024 | 745.63B |
| April 10, 2024 | 747.90B |
| April 09, 2024 | 743.39B |
| April 08, 2024 | 762.45B |
| April 05, 2024 | 769.03B |
| Date | Value |
|---|---|
| April 04, 2024 | 753.70B |
| April 03, 2024 | 761.21B |
| April 02, 2024 | 749.78B |
| April 01, 2024 | 746.54B |
| March 31, 2024 | 763.09B |
| March 28, 2024 | 762.05B |
| March 27, 2024 | 762.26B |
| March 26, 2024 | 759.14B |
| March 25, 2024 | 757.46B |
| March 22, 2024 | 755.06B |
| March 21, 2024 | 754.73B |
| March 20, 2024 | 757.20B |
| March 19, 2024 | 757.12B |
| March 18, 2024 | 747.50B |
| March 15, 2024 | 739.43B |
| March 14, 2024 | 745.67B |
| March 13, 2024 | 742.92B |
| March 12, 2024 | 740.17B |
| March 11, 2024 | 720.60B |
| March 08, 2024 | 747.01B |
| March 07, 2024 | 764.14B |
| March 06, 2024 | 763.77B |
| March 05, 2024 | 761.70B |
| March 04, 2024 | 775.66B |
| March 01, 2024 | 766.00B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
116.30B
Minimum
Oct 10 2019
775.66B
Maximum
Mar 04 2024
296.53B
Average
250.94B
Median
Enterprise Value Benchmarks
| Amgen Inc | 222.12B |
| Biogen Inc | 37.91B |
| Madrigal Pharmaceuticals Inc | 3.472B |
| Vertex Pharmaceuticals Inc | 97.95B |
| Viking Therapeutics Inc | 7.882B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.243B |
| Revenue (Quarterly) | 8.768B |
| Total Expenses (Quarterly) | 6.032B |
| EPS Diluted (Quarterly) | 2.48 |
| Gross Profit Margin (Quarterly) | 80.91% |
| Profit Margin (Quarterly) | 25.58% |
| Earnings Yield | 0.88% |
| Operating Earnings Yield | 1.75% |
| Normalized Earnings Yield | 1.334 |